Abietic acid alleviates endoplasmic reticulum stress and lipid accumulation in human primary hepatocytes through the AMPK/ORP150 signaling.
AMP-Activated Protein Kinases
/ metabolism
Abietanes
/ pharmacology
Endoplasmic Reticulum Stress
/ drug effects
HSP70 Heat-Shock Proteins
/ metabolism
Hepatocytes
/ metabolism
Humans
Hypercholesterolemia
/ metabolism
Lipid Metabolism
Liver
/ metabolism
Non-alcoholic Fatty Liver Disease
/ drug therapy
Oxygen
/ metabolism
Palmitates
/ metabolism
AMPK
Abietic acid
ER stress
NAFLD
ORP150
Journal
Biochemical and biophysical research communications
ISSN: 1090-2104
Titre abrégé: Biochem Biophys Res Commun
Pays: United States
ID NLM: 0372516
Informations de publication
Date de publication:
11 06 2022
11 06 2022
Historique:
received:
18
03
2022
accepted:
02
04
2022
pubmed:
11
4
2022
medline:
29
4
2022
entrez:
10
4
2022
Statut:
ppublish
Résumé
Abietic acid (AA), the main component of pine resin that has been traditionally used as Asian medicine, has been reported to demonstrate anti-inflammatory activities. Despite this, little is known about the effects of AA on hepatic endoplasmic reticulum (ER) stress and lipid metabolism. This study investigated the impacts of AA on ER stress and steatosis in in vitro obesity models. We found that Treatment with AA reduced lipid deposition and lipogenesis-related proteins expression in human primary hepatocytes. Augmented expression of ER stress markers (phospho-eukaryotic initiation factor-2α (eIF2α) and C/EBP homologous protein (CHOP)) in palmitate-treated hepatocytes were reversed by AA treatment. Further, AA treatment increased the expression of phospho-AMPK and oxygen-regulated protein 150 (ORP150) in hepatocytes. siRNA-associated knockdown of AMPK or ORP150 expression reduced the effects of AA on not only hepatic ER stress but also lipogenesis and apoptosis. These results denote that AA attenuates lipid accumulation in hepatocytes in the presence of palmitate through the suppression of ER stress by AMPK/ORP150 signaling. AA could be a potential candidate for treating non-alcoholic fatty liver disease.
Identifiants
pubmed: 35398611
pii: S0006-291X(22)00525-3
doi: 10.1016/j.bbrc.2022.04.010
pii:
doi:
Substances chimiques
Abietanes
0
HSP70 Heat-Shock Proteins
0
Palmitates
0
oxygen-regulated proteins
0
AMP-Activated Protein Kinases
EC 2.7.11.31
Oxygen
S88TT14065
abietic acid
V3DHX33184
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
142-148Informations de copyright
Copyright © 2022 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.